Dalton J Surmeier

List of Publications by Year in Descending Order

152 papers	19,594 citations	74 h-index	139 g-index
204 ext. papers	22,794 ext. citations	11.9 avg, IF	7.05 L-index

#	Paper	IF	Citations
152	The roles of connectivity and neuronal phenotype in determining the pattern of α-synuclein pathology in Parkinson's disease.. *Neurobiology of Disease*, **2022**, 168, 105687	7.5	1
151	Striatal synaptic adaptations in Parkinson's disease.. *Neurobiology of Disease*, **2022**, 105686	7.5	1
150	Palladium-Catalyzed α-Arylation of Cyclic β-Dicarbonyl Compounds for the Synthesis of Ca1.3 Inhibitors.. *ACS Omega*, **2022**, 7, 14252-14263	3.9	0
149	Disruption of mitochondrial complex I induces progressive parkinsonism. *Nature*, **2021**, 599, 650-656	50.4	39
148	Re-Analysis of the STEADY-PD II Trial-Evidence for Slowing the Progression of Parkinson's Disease. *Movement Disorders*, **2021**,	7	3
147	Adaptive alterations in the mesoaccumbal network after peripheral nerve injury. *Pain*, **2021**, 162, 895-908	8	9
146	Activation of the dorsal, but not the ventral, hippocampus relieves neuropathic pain in rodents. *Pain*, **2021**, 162, 2865-2880	8	7
145	Locus coeruleus anchors a trisynaptic circuit controlling fear-induced suppression of feeding. *Neuron*, **2021**, 109, 823-838.e6	13.9	14
144	Parkinson's Disease Subtypes: Critical Appraisal and Recommendations. *Journal of Parkinson's Disease*, **2021**, 11, 395-404	5.3	7
143	Isradipine plasma pharmacokinetics and exposure-response in early Parkinson's disease. *Annals of Clinical and Translational Neurology*, **2021**, 8, 603-612	5.3	13
142	Mitochondrial oxidant stress mediates methamphetamine neurotoxicity in substantia nigra dopaminergic neurons. *Neurobiology of Disease*, **2021**, 156, 105409	7.5	2
141	Seeking progress in disease modification in Parkinson disease. *Parkinsonism and Related Disorders*, **2021**, 90, 134-141	3.6	4
140	CalDAG-GEFI mediates striatal cholinergic modulation of dendritic excitability, synaptic plasticity and psychomotor behaviors. *Neurobiology of Disease*, **2021**, 158, 105473	7.5	1
139	Physiological involvement of presynaptic L-type voltage-dependent calcium channels in GABA release of cerebellar molecular layer interneurons. *Journal of Neurochemistry*, **2020**, 155, 390-402	6	4
138	Excitatory VTA to DH projections provide a valence signal to memory circuits. *Nature Communications*, **2020**, 11, 1466	17.4	8
137	Selective neuronal vulnerability in Parkinson's disease. *Progress in Brain Research*, **2020**, 252, 61-89	2.9	12
136	Striatal Kir2 K+ channel inhibition mediates the antidyskinetic effects of amantadine. *Journal of Clinical Investigation*, **2020**, 130, 2593-2601	15.9	17

135	Dopamine metabolism by a monoamine oxidase mitochondrial shuttle activates the electron transport chain. *Nature Neuroscience*, **2020**, 23, 15-20	25.5	42
134	Negative feedback control of neuronal activity by microglia. *Nature*, **2020**, 586, 417-423	50.4	179
133	Defects in mRNA Translation in LRRK2-Mutant hiPSC-Derived Dopaminergic Neurons Lead to Dysregulated Calcium Homeostasis. *Cell Stem Cell*, **2020**, 27, 633-645.e7	18	13
132	Determinants of seeding and spreading of □synuclein pathology in the brain. *Science Advances*, **2020**, 6,	14.3	25
131	A Single Amino Acid Determines the Selectivity and Efficacy of Selective Negative Allosteric Modulators of Ca1.3 L-Type Calcium Channels. *ACS Chemical Biology*, **2020**, 15, 2539-2550	4.9	8
130	Calcium, Bioenergetics, and Parkinson□ Disease. *Cells*, **2020**, 9,	7.9	23
129	Enhanced GABAergic Inhibition of Cholinergic Interneurons in the zQ175 Mouse Model of Huntington□ Disease. *Frontiers in Systems Neuroscience*, **2020**, 14, 626412	3.5	2
128	Increased Lysosomal Exocytosis Induced by Lysosomal Ca Channel Agonists Protects Human Dopaminergic Neurons from □Synuclein Toxicity. *Journal of Neuroscience*, **2019**, 39, 5760-5772	6.6	58
127	Delayed Spine Pruning of Direct Pathway Spiny Projection Neurons in a Mouse Model of Parkinson□ Disease. *Frontiers in Cellular Neuroscience*, **2019**, 13, 32	6.1	14
126	Dopaminergic modulation of striatal function and Parkinson□ disease. *Journal of Neural Transmission*, **2019**, 126, 411-422	4.3	38
125	Enhanced striatopallidal gamma-aminobutyric acid (GABA) receptor transmission in mouse models of huntington□ disease. *Movement Disorders*, **2019**, 34, 684-696	7	7
124	Maladaptive Downregulation of Autonomous Subthalamic Nucleus Activity following the Loss of Midbrain Dopamine Neurons. *Cell Reports*, **2019**, 28, 992-1002.e4	10.6	12
123	Cholinergic modulation of striatal nitric oxide-producing interneurons. *European Journal of Neuroscience*, **2019**, 50, 3713-3731	3.5	10
122	Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington□ disease. *Nature Medicine*, **2019**, 25, 1131-1142	50.5	75
121	Mutant huntingtin enhances activation of dendritic Kv4 K channels in striatal spiny projection neurons. *ELife*, **2019**, 8,	8.9	13
120	Parkinson□ disease: Is it a consequence of human brain evolution?. *Movement Disorders*, **2019**, 34, 453-459		21
119	The pedunclopontine nucleus and Parkinson□ disease. *Neurobiology of Disease*, **2019**, 128, 3-8	7.5	14
118	Cholinergic Interneurons Amplify Thalamostriatal Excitation of Striatal Indirect Pathway Neurons in Parkinson□ Disease Models. *Neuron*, **2019**, 101, 444-458.e6	13.9	44

117	Striatal synapses, circuits, and Parkinson disease. *Current Opinion in Neurobiology*, **2018**, 48, 9-16	7.6	81
116	CNTNAP2 stabilizes interneuron dendritic arbors through CASK. *Molecular Psychiatry*, **2018**, 23, 1832-1850	15.1	21
115	Striatal cholinergic interneurons and Parkinson disease. *European Journal of Neuroscience*, **2018**, 47, 1148-1158	3.5	40
114	Determinants of dopaminergic neuron loss in Parkinson disease. *FEBS Journal*, **2018**, 285, 3657-3668	5.7	127
113	Systemic isradipine treatment diminishes calcium-dependent mitochondrial oxidant stress. *Journal of Clinical Investigation*, **2018**, 128, 2266-2280	15.9	60
112	Characterization of CNTNAP2 nanostructures on interneuronal dendrites. *Molecular Psychiatry*, **2018**, 23, 1831-1831	15.1	
111	Targeting the pedunculopontine nucleus in Parkinson disease: Time to go back to the drawing board. *Movement Disorders*, **2018**, 33, 1871-1875	7	15
110	Selective neuronal vulnerability in Parkinson disease. *Nature Reviews Neuroscience*, **2017**, 18, 101-113	13.5	465
109	WAVE1 in neurons expressing the D1 dopamine receptor regulates cellular and behavioral actions of cocaine. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, 1395-1400	11.5	10
108	Cryopreservation Maintains Functionality of Human iPSC Dopamine Neurons and Rescues Parkinsonian Phenotypes In Vivo. *Stem Cell Reports*, **2017**, 9, 149-161	8	43
107	Sirt3 protects dopaminergic neurons from mitochondrial oxidative stress. *Human Molecular Genetics*, **2017**, 26, 1915-1926	5.6	53
106	Parkinson Disease Is Not Simply a Prion Disorder. *Journal of Neuroscience*, **2017**, 37, 9799-9807	6.6	113
105	Pedunculopontine glutamatergic neurons control spike patterning in substantia nigra dopaminergic neurons. *ELife*, **2017**, 6,	8.9	24
104	Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson disease. *Science*, **2017**, 357, 1255-1261	33.3	380
103	Intracellular Uncaging of cGMP with Blue Light. *ACS Chemical Neuroscience*, **2017**, 8, 2139-2144	5.7	12
102	Calcium, mitochondrial dysfunction and slowing the progression of Parkinson disease. *Experimental Neurology*, **2017**, 298, 202-209	5.7	54
101	Haloperidol Selectively Remodels Striatal Indirect Pathway Circuits. *Neuropsychopharmacology*, **2017**, 42, 963-973	8.7	14
100	Calcium and Parkinson disease. *Biochemical and Biophysical Research Communications*, **2017**, 483, 1013-1019	3.4	118

99	Synuclein-Dependent Calcium Entry Underlies Differential Sensitivity of Cultured SN and VTA Dopaminergic Neurons to a Parkinsonian Neurotoxin. *ENeuro*, **2017**, 4,	3.9	40
98	The indirect pathway of the nucleus accumbens shell amplifies neuropathic pain. *Nature Neuroscience*, **2016**, 19, 220-2	25.5	117
97	Early dysfunction and progressive degeneration of the subthalamic nucleus in mouse models of Huntington disease. *ELife*, **2016**, 5,	8.9	16
96	Cholinergic Interneurons Amplify Corticostriatal Synaptic Responses in the Q175 Model of Huntington Disease. *Frontiers in Systems Neuroscience*, **2016**, 10, 102	3.5	18
95	Transient Activation of GABAB Receptors Suppresses SK Channel Currents in Substantia Nigra Pars Compacta Dopaminergic Neurons. *PLoS ONE*, **2016**, 11, e0169044	3.7	8
94	Corticostriatal synaptic adaptations in Huntington disease. *Current Opinion in Neurobiology*, **2015**, 33, 53-62	7.6	71
93	Sodium channel Nax is a regulator in epithelial sodium homeostasis. *Science Translational Medicine*, **2015**, 7, 312ra177	17.5	40
92	M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia. *Neuron*, **2015**, 88, 762-73	13.9	129
91	Hydration status regulates sodium flux and inflammatory pathways through epithelial sodium channel (ENaC) in the skin. *Journal of Investigative Dermatology*, **2015**, 135, 796-806	4.3	37
90	Interneuronal Nitric Oxide Signaling Mediates Post-synaptic Long-Term Depression of Striatal Glutamatergic Synapses. *Cell Reports*, **2015**, 13, 1336-1342	10.6	26
89	Genetic dissection of horizontal cell inhibitory signaling in mice in complete darkness in vivo **2015**, 56, 3132-9		9
88	Functional segregation of voltage-activated calcium channels in motoneurons of the dorsal motor nucleus of the vagus. *Journal of Neurophysiology*, **2015**, 114, 1513-20	3.2	9
87	Heterosynaptic regulation of external globus pallidus inputs to the subthalamic nucleus by the motor cortex. *Neuron*, **2015**, 85, 364-76	13.9	77
86	Dopaminergic modulation of striatal networks in health and Parkinson disease. *Current Opinion in Neurobiology*, **2014**, 29, 109-17	7.6	93
85	Cell type-specific plasticity of striatal projection neurons in parkinsonism and L-DOPA-induced dyskinesia. *Nature Communications*, **2014**, 5, 5316	17.4	181
84	Impaired TrkB receptor signaling underlies corticostriatal dysfunction in Huntington disease. *Neuron*, **2014**, 83, 178-88	13.9	128
83	Mitochondrial oxidant stress in locus coeruleus is regulated by activity and nitric oxide synthase. *Nature Neuroscience*, **2014**, 17, 832-40	25.5	102
82	Impaired striatal function in Huntington disease is due to aberrant p75NTR signaling. *Rare Diseases (Austin, Tex)*, **2014**, 2, e968482		2

81	Nitric oxide regulates synaptic transmission between spiny projection neurons. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 17636-41	11.5	20
80	Molecular adaptations of striatal spiny projection neurons during levodopa-induced dyskinesia. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 4578-83	11.5	81
79	Neuronal vulnerability, pathogenesis, and Parkinson disease. *Movement Disorders*, **2013**, 28, 41-50	7	121
78	Neuronal vulnerability, pathogenesis, and Parkinson disease. *Movement Disorders*, **2013**, 28, 715-24	7	105
77	The pathology roadmap in Parkinson disease. *Prion*, **2013**, 7, 85-91	2.3	51
76	Structure-activity relationship of N,N-disubstituted pyrimidinetriones as Ca(V)1.3 calcium channel-selective antagonists for Parkinson disease. *Journal of Medicinal Chemistry*, **2013**, 56, 4786-97	8.3	24
75	Calcium entry and -synuclein inclusions elevate dendritic mitochondrial oxidant stress in dopaminergic neurons. *Journal of Neuroscience*, **2013**, 33, 10154-64	6.6	144
74	Convergent cortical innervation of striatal projection neurons. *Nature Neuroscience*, **2013**, 16, 665-7	25.5	109
73	Regulation of dendritic calcium release in striatal spiny projection neurons. *Journal of Neurophysiology*, **2013**, 110, 2325-36	3.2	33
72	Calcium, bioenergetics, and neuronal vulnerability in Parkinson disease. *Journal of Biological Chemistry*, **2013**, 288, 10736-41	5.4	149
71	Adenosine A2a receptor antagonists attenuate striatal adaptations following dopamine depletion. *Neurobiology of Disease*, **2012**, 45, 409-16	7.5	28
70	Calcium entry induces mitochondrial oxidant stress in vagal neurons at risk in Parkinson disease. *Nature Neuroscience*, **2012**, 15, 1414-21	25.5	120
69	CaV1.3-selective L-type calcium channel antagonists as potential new therapeutics for Parkinson disease. *Nature Communications*, **2012**, 3, 1146	17.4	114
68	A feud that wasn: acetylcholine evokes dopamine release in the striatum. *Neuron*, **2012**, 75, 1-3	13.9	28
67	Neurochemical characterization of the striatum and the nucleus accumbens in L-type Ca(v)1.3 channels knockout mice. *Neurochemistry International*, **2012**, 60, 229-32	4.4	4
66	Sensorimotor assessment of the unilateral 6-hydroxydopamine mouse model of Parkinson disease. *Behavioural Brain Research*, **2012**, 230, 309-16	3.4	87
65	Muscarinic modulation of striatal function and circuitry. *Handbook of Experimental Pharmacology*, **2012**, 223-41	3.2	102
64	Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson disease. *Science Translational Medicine*, **2012**, 4, 141ra90	17.5	381

63	Physiological phenotype and vulnerability in Parkinson's disease. *Cold Spring Harbor Perspectives in Medicine*, **2012**, 2, a009290	5.4	83
62	Strain-specific regulation of striatal phenotype in Drd2-eGFP BAC transgenic mice. *Journal of Neuroscience*, **2012**, 32, 9124-32	6.6	54
61	The origins of oxidant stress in Parkinson's disease and therapeutic strategies. *Antioxidants and Redox Signaling*, **2011**, 14, 1289-301	8.4	118
60	Synaptically driven state transitions in distal dendrites of striatal spiny neurons. *Nature Neuroscience*, **2011**, 14, 881-8	25.5	99
59	HCN channelopathy in external globus pallidus neurons in models of Parkinson's disease. *Nature Neuroscience*, **2011**, 14, 85-92	25.5	129
58	Modulation of striatal projection systems by dopamine. *Annual Review of Neuroscience*, **2011**, 34, 441-66	17	1033
57	Thalamic contributions to Basal Ganglia-related behavioral switching and reinforcement. *Journal of Neuroscience*, **2011**, 31, 16102-6	6.6	80
56	Brain networks in Huntington disease. *Journal of Clinical Investigation*, **2011**, 121, 484-92	15.9	54
55	Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1. *Nature*, **2010**, 468, 696-700	50.4	595
54	The role of dopamine in modulating the structure and function of striatal circuits. *Progress in Brain Research*, **2010**, 183, 149-67	2.9	52
53	MEF-2 regulates activity-dependent spine loss in striatopallidal medium spiny neurons. *Molecular and Cellular Neurosciences*, **2010**, 44, 94-108	4.8	84
52	alpha-Synuclein at the synaptic gate. *Neuron*, **2010**, 65, 3-4	13.9	9
51	Thalamic gating of corticostriatal signaling by cholinergic interneurons. *Neuron*, **2010**, 67, 294-307	13.9	320
50	What causes the death of dopaminergic neurons in Parkinson's disease?. *Progress in Brain Research*, **2010**, 183, 59-77	2.9	88
49	Calcium, cellular aging, and selective neuronal vulnerability in Parkinson's disease. *Cell Calcium*, **2010**, 47, 175-82	4	154
48	A molecular basis for the increased vulnerability of substantia nigra dopamine neurons in aging and Parkinson's disease. *Movement Disorders*, **2010**, 25 Suppl 1, S63-70	7	78
47	Tolerability of isradipine in early Parkinson's disease: a pilot dose escalation study. *Movement Disorders*, **2010**, 25, 2863-6	7	53
46	Robust pacemaking in substantia nigra dopaminergic neurons. *Journal of Neuroscience*, **2009**, 29, 11011-9	6.6	273

45	Dopamine and synaptic plasticity in dorsal striatal circuits controlling action selection. *Current Opinion in Neurobiology*, **2009**, 19, 621-8	7.6	131
44	Balancing excitation, inhibition and endocannabinoids (Commentary on Ademark et al.). *European Journal of Neuroscience*, **2009**, 29, 31	3.5	1
43	Calcium homeostasis, selective vulnerability and Parkinson disease. *Trends in Neurosciences*, **2009**, 32, 249-56	13.3	175
42	A lethal convergence of dopamine and calcium. *Neuron*, **2009**, 62, 163-4	13.9	8
41	Antagonizing L-type Ca2+ channel reduces development of abnormal involuntary movement in the rat model of L-3,4-dihydroxyphenylalanine-induced dyskinesia. *Biological Psychiatry*, **2009**, 65, 518-26	7.9	66
40	FGF acts as a co-transmitter through adenosine A(2A) receptor to regulate synaptic plasticity. *Nature Neuroscience*, **2008**, 11, 1402-9	25.5	146
39	A translational profiling approach for the molecular characterization of CNS cell types. *Cell*, **2008**, 135, 738-48	56.2	796
38	Dichotomous dopaminergic control of striatal synaptic plasticity. *Science*, **2008**, 321, 848-51	33.3	848
37	Differential excitability and modulation of striatal medium spiny neuron dendrites. *Journal of Neuroscience*, **2008**, 28, 11603-14	6.6	177
36	Dichotomous anatomical properties of adult striatal medium spiny neurons. *Journal of Neuroscience* , **2008**, 28, 10814-24	6.6	320
35	Corticostriatal and thalamostriatal synapses have distinctive properties. *Journal of Neuroscience*, **2008**, 28, 6483-92	6.6	211
34	Recurrent collateral connections of striatal medium spiny neurons are disrupted in models of Parkinson disease. *Journal of Neuroscience*, **2008**, 28, 5504-12	6.6	270
33	Dopamine and working memory mechanisms in prefrontal cortex. *Journal of Physiology*, **2007**, 581, 885	3.9	19
32	Cholinergic modulation of Kir2 channels selectively elevates dendritic excitability in striatopallidal neurons. *Nature Neuroscience*, **2007**, 10, 1458-66	25.5	204
31	Rejuvenation protects neurons in mouse models of Parkinson disease. *Nature*, **2007**, 447, 1081-6	50.4	670
30	Calcium, ageing, and neuronal vulnerability in Parkinson disease. *Lancet Neurology, The*, **2007**, 6, 933-8	24.1	213
29	Nav1.6 sodium channels are critical to pacemaking and fast spiking in globus pallidus neurons. *Journal of Neuroscience*, **2007**, 27, 13552-66	6.6	87
28	D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. *Trends in Neurosciences*, **2007**, 30, 228-35	13.3	822

27	Re-emergence of striatal cholinergic interneurons in movement disorders. *Trends in Neurosciences*, **2007**, 30, 545-53	13.3	343
26	Dopaminergic control of corticostriatal long-term synaptic depression in medium spiny neurons is mediated by cholinergic interneurons. *Neuron*, **2006**, 50, 443-52	13.9	409
25	Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models. *Nature Neuroscience*, **2006**, 9, 251-9	25.5	598
24	RGS4-dependent attenuation of M4 autoreceptor function in striatal cholinergic interneurons following dopamine depletion. *Nature Neuroscience*, **2006**, 9, 832-42	25.5	190
23	Striatal information signaling and integration in globus pallidus: timing matters. *NeuroSignals*, **2005**, 14, 281-9	1.9	24
22	Autonomous pacemakers in the basal ganglia: who needs excitatory synapses anyway?. *Current Opinion in Neurobiology*, **2005**, 15, 312-8	7.6	99
21	Cholinergic suppression of KCNQ channel currents enhances excitability of striatal medium spiny neurons. *Journal of Neuroscience*, **2005**, 25, 7449-58	6.6	169
20	G-protein-coupled receptor modulation of striatal CaV1.3 L-type Ca2+ channels is dependent on a Shank-binding domain. *Journal of Neuroscience*, **2005**, 25, 1050-62	6.6	212
19	RGS9-2 modulates D2 dopamine receptor-mediated Ca2+ channel inhibition in rat striatal cholinergic interneurons. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 16339-44	11.5	86
18	HCN2 and HCN1 channels govern the regularity of autonomous pacemaking and synaptic resetting in globus pallidus neurons. *Journal of Neuroscience*, **2004**, 24, 9921-32	6.6	138
17	Homeostatic regulation of dopaminergic neurons without dopamine. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 13103-4	11.5	
16	D2 dopamine receptor-mediated modulation of voltage-dependent Na+ channels reduces autonomous activity in striatal cholinergic interneurons. *Journal of Neuroscience*, **2004**, 24, 10289-301	6.6	165
15	Peering into the dendritic machinery of striatal medium spiny neurons. *Neuron*, **2004**, 44, 401-2	13.9	2
14	Kv3.4 subunits enhance the repolarizing efficiency of Kv3.1 channels in fast-spiking neurons. *Nature Neuroscience*, **2003**, 6, 258-66	25.5	119
13	"The little engine that could": voltage-dependent Na(+) channels and the subthalamic nucleus. *Neuron*, **2003**, 39, 5-6	13.9	5
12	Transmitter modulation of slow, activity-dependent alterations in sodium channel availability endows neurons with a novel form of cellular plasticity. *Neuron*, **2003**, 39, 793-806	13.9	140
11	D1/D5 dopamine receptor activation differentially modulates rapidly inactivating and persistent sodium currents in prefrontal cortex pyramidal neurons. *Journal of Neuroscience*, **2001**, 21, 2268-77	6.6	187
10	D2 dopamine receptors in striatal medium spiny neurons reduce L-type Ca2+ currents and excitability via a novel PLC[beta]1-IP3-calcineurin-signaling cascade. *Journal of Neuroscience*, **2000**, 20, 8987-95	6.6	416

9	Unique properties of R-type calcium currents in neocortical and neostriatal neurons. *Journal of Neurophysiology*, **2000**, 84, 2225-36	3.2	60
8	Dopaminergic modulation of neuronal excitability in the striatum and nucleus accumbens. *Annual Review of Neuroscience*, **2000**, 23, 185-215	17	759
7	Delayed rectifier currents in rat globus pallidus neurons are attributable to Kv2.1 and Kv3.1/3.2 K(+) channels. *Journal of Neuroscience*, **1999**, 19, 6394-404	6.6	100
6	Serotonergic modulation of hyperpolarization-activated current in acutely isolated rat dorsal root ganglion neurons. *Journal of Physiology*, **1999**, 518 (Pt 2), 507-23	3.9	103
5	Expression of the transcription factor deltaFosB in the brain controls sensitivity to cocaine. *Nature*, **1999**, 401, 272-6	50.4	534
4	Selective blockade of a slowly inactivating potassium current in striatal neurons by (+/-) 6-chloro-APB hydrobromide (SKF82958). *Synapse*, **1998**, 29, 213-24	2.4	38
3	D2 dopamine receptors reduce N-type Ca2+ currents in rat neostriatal cholinergic interneurons through a membrane-delimited, protein-kinase-C-insensitive pathway. *Journal of Neurophysiology*, **1997**, 77, 1003-15	3.2	222
2	Coordinated expression of dopamine receptors in neostriatal medium spiny neurons. *Journal of Neuroscience*, **1996**, 16, 6579-91	6.6	631
1	Muscarinic modulation of a transient K+ conductance in rat neostriatal neurons. *Nature*, **1990**, 344, 240-2	50.4	134